# UZH Life Sciences Fund

> UZH Life Sciences Fund is a VC fund backing Health Care and Biotechnology. See 6 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Zürich, Switzerland
- Total investments: 6
- Last investment: May 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/university-of-zurich-uzh-foundation/
- Website: http://www.uzhfoundation.ch/

UZH Life Sciences Fund is a VC fund in Zürich focused on Health Care and Biotechnology. The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.

## Contacts

5 contacts available for UZH Life Sciences Fund. Shizune tracks 1 team members at UZH Life Sciences Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/uzh-life-sciences-fund?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $1.2M–$1.2M |
| Convertible Note | $1M–$1.1M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 67% |
| Biotechnology | 4 | 67% |
| Medical | 2 | 33% |
| Medical Device | 2 | 33% |
| Beauty | 1 | 17% |

12 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 33% |
| Funding Round | 2 | 33% |
| Convertible Note | 2 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Michio Painter | Board Secretary | 3 | https://shizune.co/investors/profile/michio-painter-15a2 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| metaLead Therapeutics | metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment. | $1.2M | Seed | May 06, 2025 |  |
| FimmCyte | FimmCyte develops a novel disease modifying treatments for fibro-inflammatory diseases, starting with Endometriosis. | $1.1M | Convertible Note | Feb 28, 2024 |  |
| Navignostics | Our mission is to identify the ideal treatment to battle each cancer patient’s disease and reduce suffering throughout their journey.At Navignostics we characterize tumors using spatial single-cell proteomics. We use our unique capabilities to identify a cancer treatment that will optimally fight each patient’s tumor. We also accelerate cancerdrug development by providing key insights into drug mechanisms and tumor features for companion diagnostic development.Our highly robust and reliable technology and our leading data analytics position us ideally to enable precision cancer diagnostics for patients and to provide services to pharma and biotech partners.This way we help people suffering from cancer by making more drugs available and by finding the right one for every patient. | $1M | Convertible Note | Aug 29, 2022 |  |
| Occlufit | Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects. |  |  | Jan 01, 2019 |  |
| ImmunOs Therapeutics | ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. |  |  | Oct 01, 2018 |  |
| Cutiss | CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns. | $1.2M | Seed | Aug 30, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 1 deal together
- [Schroder Adveq](https://shizune.co/investors/profile/schroder-adveq) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Unilever Ventures](https://shizune.co/investors/profile/unilever-ventures) — VC Fund
- [Fab Co-Creation Studio Ventures](https://shizune.co/investors/profile/fab-co-creation-studio-ventures) — VC Fund
- [Flybridge](https://shizune.co/investors/profile/flybridge-capital) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SICTIC](https://shizune.co/investors/profile/sictic) — VC Fund
- [Zürcher Kantonal Bank](https://shizune.co/investors/profile/z%C3%BCrcher-kantonalbank) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund

## Featured in investor lists
- [Medical Device Investors in Switzerland](https://shizune.co/investors/medical-device-investors-switzerland)
- [Life Science Investors in Switzerland](https://shizune.co/investors/life-science-investors-switzerland)
- [Beauty Investors in Switzerland](https://shizune.co/investors/beauty-investors-switzerland)
- [Beauty VC Funds in Switzerland](https://shizune.co/investors/beauty-vc-funds-switzerland)

## FAQ

### What does UZH Life Sciences Fund invest in?

UZH Life Sciences Fund invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Funding Round stage. Most of the 6 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is UZH Life Sciences Fund's check size?

UZH Life Sciences Fund typically joins rounds of $1.2M–$1.2M at Seed and $1M–$1.1M at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds UZH Life Sciences Fund participates in.

### How do I contact UZH Life Sciences Fund?

Public channels for UZH Life Sciences Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at UZH Life Sciences Fund?

The team at UZH Life Sciences Fund includes Michio Painter (Board Secretary). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co